2. 筋萎縮性側索硬化症 Amyotrophic lateral sclerosis Clinical trials / Disease details
|June 19, 2017||31/1/2017||MIROCALS: Modifying Immune Response and OutComes in ALS||Efficacy and Safety of Low-dose IL-2 (Ld-IL-2) as a Treg Enhancer for Controlling Neuro-inflammation in Newly Diagnosed Amyotrophic Lateral Sclerosis (ALS) Patients: A Randomized, Double-blind, Placebo- Controlled, Phase-II Proof of Concept/ Proof of Mechanism Clinical Trial||Amyotrophic Lateral Sclerosis||Drug: Riluzole;Drug: IL-2;Drug: 5% glucose water solution||Centre Hospitalier Universitaire de Nimes||NULL||Completed||18 Years||75 Years||All||304||Phase 2||France;United Kingdom|
|2||JPRN-UMIN000019111||2015/10/01||01/10/2015||CaHMB L-arginine-glutamine blended drinks (Abound (TM)) for amyotrophic lateral sclerosis patients and sarcopenia improvement effect by drinking.||Amyotrophic lateral sclerosis||Abound(TM)|
1,Take one pack twice a day in the moring and evening
2,Drinking was dissolved in water 240 ~ 300ml
3,Before meals, after meals does not matter
|National Hospital Organization Takasaki General Medical Center||NULL||Recruiting||Not applicable||Not applicable||Male and Female||20||Not selected||Japan|
|3||JPRN-UMIN000015054||2014/09/21||04/09/2014||An investigator initiated clinical trial in healthy adults to evaluate safety and pharmacokinetics of WN1316, a candidate drug of amyotrophic lateral sclerosis||Amyotrophic Lateral Sclerosis (ALS)||WN1316 solution 5mL is administered single dose orally.|
The dosage of WN1316 is 60 micrograms in step 1, 180 micrograms in step 2, 600 micrograms in step 3.
Placebo (Distilled water) 5 mL is administered single dose orally.
|Clinical Research Hospital Tokyo||NULL||Complete: follow-up complete||20years-old||35years-old||Male||24||Not selected||Japan|